Pain is a significant public health problem, affecting more than 100 million adults in the US and causing significant reductions in patients' quality of life. The use of narcotic medications for pain management has increased dramatically in the US over the past two decades. However, pain patients are often undertreated due to a variety of physician- and patient-related concerns and barriers.
In addition, despite the pain-relieving properties of opioid medications, the potential for abuse remains a concern. In response to this apprehension about opioid misuse, overdose, abuse, and addiction, the Food and Drug Administration (FDA) developed the Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the risks for long-acting and extended-release opioid analgesics.
This activity, A Comprehensive Approach to the Safe Management of Extended-Release/Long-Acting Opioids, incorporates the REMS blueprint into education that is designed to induce changes in knowledge, competence, and performance that will translate into improved quality of patient care and reduced pain for patients.
This activity will be presented at the following PAINWeekEND locations:
This education is intended for PCPs, and is designed to help them recognize and balance optimal pain reduction to improve function and productivity with minimization of adverse events (e.g. abuse, addiction, and risk of workplace accidents). Additional challenges to optimal pain management include keeping up to date with the increasing volume of information on pain management, implementing changes recommended by evolving guidelines, and recognizing changes to practice needed to combat the growing rate of opioid abuse.
This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Rockpointe Corporation. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.
This educational activity for 3.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 3.0 contact hours (0.3 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-16-001-L01-P).
This is a knowledge based activity.
Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 1101021. This program has been approved for 3.0 contact hours of continuing education (which includes X.X hours of pharmacology).
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(TM) from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 3.0 hours of Category 1 credit for completing this program.
To receive credit learners must complete pre-test, post-test, and evaluation.
There is no fee for this educational activity.
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Jeffrey A. Gudin, MD||Consultant/Independent Contractor: Daiichi, Depomed, Insys, KemPharm, Quest Diagnostics, Scilex, Shionogi Grant/Research: KemPharm, Sentanyl Speakers' Bureau: AstraZeneca, Iroko, Purdue, Teva, Xenoport|
|Steven D. Passik, PhD||Full time employee of: Millennium Health|
|Lynn Webster, MD||Consultant/Independent Contractor: AstraZeneca, Cara Therapeutics, Mallinckrodt, Marathon, Merck, Proove Biosciences, Zogenix Honoraria: Charleston Labs, Collegium Pharmaceuticals, Egalet, Inspirion, Insys Therapeutics, Kaleo, Orexo, Pfizer, Proove Biosciences, Signature Therapeutics, Trevena Other/Travel Expenses: AstraZeneca, Cara Therapeutics, Charleston Labs, Collegium Pharmaceuticals, Insys Therapeutics, Kaleo, Mallinckrodt, Orexo, Pfizer, Proove Biosciences, Teva, Trevena, Zogenix|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Planner or Manager||Reported Financial Relationship|
|Ashley Marostica, RN, MSN||Nothing to disclose|
|Kristen Delisi||Nothing to disclose|
|Amanda Glazar, PhD||Nothing to disclose|
|Andrea Funk||Nothing to disclose|
|Laura Gilsdorf, MS||Nothing to disclose|
|Matthew Horn, MD||Nothing to disclose|
|Blair St. Amand||Nothing to disclose|
|Jay M. Katz, MA, CHCP||Nothing to disclose|
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Rockpointe Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Rockpointe Corporation.
This educational activity is supported by an independent educational grant from the ER/LS Opioid Analgesic REMS Program Companies.
Please see: http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.
This program was planned in accordance with AANP CE Standards and Policies and the AANP Commercial Support Standard.
Jeffrey A. Gudin, MD Director Pain Management Center
Englewood Hospital and Medical Center
Lynn Webster, MD Vice President of Scientific Affairs
PRA Health Sciences
Salt Lake City, UT
Steven D. Passik, PhD Pain Psychologist
San Diego, CA